Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

20051,165 citationsJournal Articlebronze Open Access

Authors

Aman U. Buzdar · The University of Texas MD Anderson Cancer Center

Nuhad K. Ibrahim · The University of Texas MD Anderson Cancer Center

Deborah Francis · The University of Texas MD Anderson Cancer Center

Daniel J. Booser · The University of Texas MD Anderson Cancer Center

Eva Thomas · The University of Texas MD Anderson Cancer Center

Richard L. Theriault · The University of Texas MD Anderson Cancer Center

Abstract

Despite the small sample size, these data indicate that adding trastuzumab to chemotherapy, as used in this trial, significantly increased pCR without clinical congestive heart failure.

Topics & Keywords

HER2/EGFR in Cancer Research Peptidase Inhibition and Analysis Cancer Treatment and Pharmacology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 23, Issue 16, pp. 3676-3685

DOI: 10.1200/jco.2005.07.032

Field-Weighted Citation Impact: 36.50